Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China

by Jing Ni, Xianzhong Cheng, Rui Zhou, Xia Xu, Wenwen Guo, Xiaoxiang Chen
Published 2019-11-01

Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series

by Jing Ni, Rui Zhou, Xianzhong Cheng, Xia Xu, Wenwen Guo, Xiaoxiang Chen
Published 2020-03-01

The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial

by Hongyuan Gu, Rui Zhou, Jing Ni, Xia Xu, Xianzhong Cheng, Yan Li, Xiaoxiang Chen
Published 2020-06-01

Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor

by Jing Ni, Xianzhong Cheng, Rui Zhou, Qian Zhao, Xia Xu, Wenwen Guo, Hongyuan Gu, Chen Chen, Xiaoxiang Chen
Published 2021-09-01

The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China

by Jing Ni, Xianzhong Cheng, Qian Zhao, Zhiqin Dai, Xia Xu, Wenwen Guo, Hongyuan Gu, Rui Zhou, Yan Wang, Xiaoxiang Chen
Published 2021-05-01

Case Report: Extragonadal Yolk Sac Tumors Originating From the Endometrium and the Broad Ligament: A Case Series and Literature Review

by Xianzhong Cheng, Qian Zhao, Xia Xu, Wenwen Guo, Hongyuan Gu, Rui Zhou, Chen Chen, Dawei Ma, Yinan Wu, Jing Ni, Xiaoxiang Chen
Published 2021-06-01